Wednesday January 5
Serono's Rebif MS drug, Teva's Copaxone to go head-to-head in test
ZURICH (AFX) - Serono SA said it has completed patient enrollment for its planned head-to-head comparative trial of its Rebif drug with Teva Pharmaceutical Industries Ltd's Copaxone in the treatment of relapsing remitting multiple sclerosis (RRMS).
700 patients have been enrolled to take part in the two-year test, the Swiss biotech group said in a statement.
A previous head-to-head comparing Rebif ...